Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741928 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL6742009 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL6738931 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL7676803 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL6739639 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL2272539 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL6742008 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL6740957 | 1.00 | L3MBTL1 (0.31) | L3MBTL1LMNATDP1 | |
| SCHEMBL8336824 | 0.89 | L3MBTL1 (0.35) | L3MBTL1LMNATDP1 | |
| SCHEMBL8336204 | 0.89 | L3MBTL1 (0.35) | L3MBTL1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209890-A1 | Polyhydroxyalkylpyrazine derivatives, their preparation and medicaments comprising them | BASHIARDES GEORGES | 2004-10-21 | — | — | US | claimed |
| EP-0998465-B1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-09-10 | — | — | EP | claimed |
| US-6392042-B1 | ANTIDIABETIC AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-05-21 | — | — | US | claimed |
| US-20040209890-A1 | Polyhydroxyalkylpyrazine derivatives, their preparation and medicaments comprising them | BASHIARDES GEORGES | 2004-10-21 | — | — | US | disclosed |
| EP-0998465-B1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-09-10 | — | — | EP | disclosed |
| US-6392042-B1 | ANTIDIABETIC AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209890-A1 | Polyhydroxyalkylpyrazine derivatives, their preparation and medicaments comprising them | SLC5A2, HK2, HRH2 | L3MBTL1 4794/4885LMNA 4447/4885TDP1 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.